Molecularly targeted therapy for melanoma
Authors:
Open Access
Abstract
Effective therapy for melanoma remains an unmet goal, with most traditional therapies representing inadequate trade‐offs among the several goals of specificity, efficacy, and toxicity. Targeted molecular therapeutics are tailored to genetic abnormalities that are associated with tumor progression. Modulation of aberrant signaling pathways in cancer cells has the potential to provide more effective and potentially nontoxic therapy for a broad range of cancers, including melanoma. Among the possible targets in melanoma are the Ras‐MAPK and PI3K/AKT signal transduction pathways, the proteasome, histone deacetylases, methyltransferases, and melanoma‐induced angiogenesis. Cancer 2006. © 2006 American Cancer Society.Keywords
This publication has 56 references indexed in Scilit:
- Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysisBritish Journal of Cancer, 2006
- Molecular Targets in Melanoma from Angiogenesis to ApoptosisClinical Cancer Research, 2006
- The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycleCell Death & Differentiation, 2005
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005
- Temozolomide plus thalidomide in patients with brain metastases from melanomaCancer, 2005
- Improving Outcomes in Advanced Malignant MelanomaDrugs, 2005
- Cancer genes and the pathways they controlNature Medicine, 2004
- Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins αvβ3 and αvβ5 in patients with advanced solid tumoursEuropean Journal of Cancer, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Mutations of the BRAF gene in human cancerNature, 2002